APOA1 and atherosclerosis: In recent animal studies, apoA-I was shown to decrease the occurrence and progression of neo-atherosclerosis and ISR by inhibiting inflammation, smooth muscle cell (SMC) proliferation, angiogenesis, and platelet activation [13–19].